CHICO, Calif.--(BUSINESS WIRE)--PinPointe™ FootLaser™ today announced that it has received CE Mark approval for its new treatment for toenail fungus (Onychomycosis), certifying that it has met EU consumer and health safety standards and can be offered by certified health care providers throughout Europe.
PinPointe FootLaser uses a patented laser technology to treat toenail fungus (Onychomycosis), an infection that afflicts an estimated 900 million people around the world. With PinPointe FootLaser, patients are treated quickly and effectively with no oral or systemic drugs and no anesthesia. PinPointe’s laser light passes through the toenail without causing damage to the nail or surrounding skin. The procedure allows the new nail to grow in healthy and clear. Unlike competing medication-driven treatments for toenail fungus, PinPointe FootLaser presents minimal risk of side effects.
By offering a simple, non-invasive solution for patients suffering from toenail fungus, PinPointe FootLaser offers licensed healthcare providers an excellent opportunity for building their practice and providing a valuable service to their patients. PinPointe FootLaser is an emerging leader in the medical technology industry.
About PathoLase
Founded in 2004, PathoLase, Inc. is a privately held emerging medical technology company with headquarters in Northern California. PathoLase has assembled a world-class group of top scientists, academic thought leaders and leading practitioners from around the U.S. and Canada to develop and bring to market a new generation of laser technology solutions that address a series of medical issues, from toenail fungus and periodontal disease to more serious life threatening problems, such as blood borne and respiratory infections. For more information please visit http://www.pinpointefootlaser.com/eu
Contact:
Media: DBA Public Relations Matthew Calderone U.S. Phone: (212) 388-1400 ext. 29 mcalderone@dba-pr.com
